Compositions and methods for use in targeting vascular destruction

US6956054B2 · kind B2 · utility

Assignees

• Baylor University · US
• OXiGENE, Inc. · US

Inventors

• Ronald W. Pero · Lund, SE
• David Sherris · Brookline, US
• Kevin G. Pinney · Woodway, US
• Vani P. Mocharla · Los Angeles, US
• Zhi Chen · Seattle, US

Key dates

• Filing date: Aug 14, 2002
• Grant date: Oct 18, 2005
• Expiry date: Jan 5, 2023

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Treatment of warm-blooded animals having a tumor or non-malignant hypervascularation, by administering a sufficient amount of a cytotoxic agent formulated into a phosphate prodrug form having substrate specificity for microvessel phosphatases, so that microvessels are destroyed preferentially over other normal tissues, because the less cytotoxic prodrug form is converted to the highly cytotoxic dephosphorylated form.